Clinical trial · Observational
Glioblastoma Response Prediction to Apatinib
Study on Predicting Response of Recurrent Glioblastoma to Apatinib
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal antibody against VEGFR-2, when added to temozolomide chemotherapy in patients with recurrent glioblastoma. Some patients showed durable responses and prolonged survival, with recorded survival times of over 30 months in 6.4% patients. However, a subset of patients progressed in 2 months. There is a strong need to better predict and monitor apatinib treatment response to prevent patients from adverse effects of ineffective therapy. In this study, whole genome sequencing and RNA-sequencing of formalin-fixed, paraffin-embedded tumor materials from the participants who received apatinib and temozolomide treatment will be performed to identify the response biomarkers and patients who may benefit most from apatinib, avoiding unnecessary potential toxicity and cost for those who are unlikely to benefit from the drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| genetic characteristic | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- effective group
- description
- After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
- interventionNames
- Other: genetic characteristic
- label
- stable group
- description
- After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
- interventionNames
- Other: genetic characteristic
- label
- Early progressed group
- description
- After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
- interventionNames
- Other: genetic characteristic
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-70 years old 2. recurrent glioblastoma 3. received apatinib plus temozolomide treatment，response and survival data were available 4. tumor tissues were acquired Exclusion Criteria: \-
References
Publications (0)
Data not yet available